key: cord-0873040-r7kvv48s
authors: Tan, Anthony T.; Linster, Martin; Tan, Chee Wah; Le Bert, Nina; Chia, Wan Ni; Kunasegaran, Kamini; Zhuang, Yan; Tham, Christine Y.L.; Chia, Adeline; Smith, Gavin JD.; Young, Barnaby; Kalimuddin, Shirin; Low, Jenny G.H.; Lye, David; Wang, Lin-Fa; Bertoletti, Antonio
title: Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
date: 2021-01-21
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.108728
sha: e23178dfa88ed434748f438e1a2ccceef7e8732f
doc_id: 873040
cord_uid: r7kvv48s

Virus-specific humoral and cellular immunity act synergistically to protect the host from viral infection. We interrogate the dynamic changes of virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to convalescence or death. We quantify SARS-CoV-2 viral RNA in the respiratory tract in parallel with antibodies and circulating T cells specific for various structural (NP, M, ORF3a and spike) and non-structural proteins (ORF7/8, NSP7 and NSP13). While rapid induction and quantity of humoral responses associates with an increase in disease severity, early induction of IFN-γ secreting SARS-CoV-2 specific T cells is present in patients with mild disease and accelerated viral clearance. These findings provide support for the prognostic value of early functional SARS-CoV-2 specific T cells with important implications in vaccine design and immune monitoring.

Virus-specific humoral and cellular immunity act synergistically to protect the host from viral 2 infection. We interrogate the dynamic changes of virological and immunological parameters 3 in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to 4 convalescence or death. We quantify SARS-CoV-2 viral RNA in the respiratory tract in 5 parallel with antibodies and circulating T cells specific for various structural (NP, M, ORF3a 6 and spike) and non-structural proteins (ORF7/8, NSP7 and NSP13). While rapid induction 7 and quantity of humoral responses associates with an increase in disease severity, early 8 induction of IFN-γ secreting SARS-CoV-2 specific T cells is present in patients with mild 9 disease and accelerated viral clearance. These findings provide support for the prognostic 10 Introduction 1 In December 2019, a new coronavirus was detected in Wuhan, China in several patients 2 with pneumonia and was later named SARS-CoV-2 (Zhou et al., 2020a) . The illness (COVID- 3 19) resulting from SARS-CoV-2 infection is reported to be multi-faceted with inflammation 4 of the respiratory tract causing the leading symptoms of fever and dry cough (Chen et al., 5 2020) . Both virus-specific humoral (Long et al., 2020a) (Gudbjartsson et al., 2020; Sun et al., 6 2020) and cellular (Grifoni et al., 2020) (Braun et al., 2020; Le Bert et al., 2020) (Weiskopf et 7 al., 2020) components of adaptive immunity are induced in SARS-CoV-2 infected individuals 8 but their roles in viral control or disease pathogenesis still needs to be clarified. Viral 9 clearance and reduced disease severity have been associated with a coordinated activation 10 of humoral and cellular anti-viral immunity (Rydyznski Moderbacher et al., 2020) and robust 11 virus-specific T cell responses (Takahashi et al., 2020) . On the other hand, a positive relation 12 between the magnitude of SARS-CoV-2 antibodies (Hung et al., 2020; Long et al., 2020b) 13 (Wang et al., 2020) or T cells (Peng et al., 2020) with disease severity have also been 14 reported. However, most of these studies have analysed patients during the convalescent 15 phase of infection and only few studies have reported the dynamic changes of viral and 16 virus-specific immunological parameters in severe COVID-19 patients during the initial 17 phases of infection (Weiskopf et al., 2020) (Rydyznski Moderbacher et al., 2020; Zhou et al., 18 2020b). To fill this gap, we longitudinally followed-up twelve patients (Supplementary Table   19 1) with SARS-CoV-2 infection from symptom onset to convalescence or death. We quantified 20 SARS-CoV-2 viral load in the upper respiratory tract and SARS-Cov-2 specific antibodies and 21 T cells at multiple time points from acute disease till convalescence or death. Our data 22 reveal a direct association between early induction of functional SARS-CoV-2 specific T cells 23 and rapid control of viral infection. symptom onset. Five (P11, 16, 06, 09 and 03) were RT-PCR negative at around day 17-24, 10 while two (P10 and 12) became RT-PCR negative almost 1 month after onset of symptoms. 11 One patient (P05) who succumbed to infection was persistently SARS-CoV-2 RT-PCR positive 12 till day 31 post symptom onset when he demised. Peak viral quantities was also positively 13 correlated with the duration of infection (Figure 1 insert). In addition, while patients who 14 eliminated the virus within 15 days experienced mild respiratory symptoms (presence of 15 fever or respiratory symptoms but not requiring supplemental oxygen), patients with 16 moderate (requiring oxygen supplementation FiO2<0.5) and severe (requiring oxygen 17 supplementation FiO2>0.5, high flow oxygen and/or mechanical ventilation) symptoms 18 eliminated the virus from upper respiratory tract later. Viral load detected in patients with 19 mild symptoms were also lower than those with moderate/severe symptoms 20 (Supplementary Figure 1A) . 21 

J o u r n a l P r e -p r o o f 1 We then characterized the kinetics of anti-SARS-CoV-2 antibody appearance. Virus 2 neutralization ability was tested longitudinally utilizing the surrogate virus neutralization 3 test (sVNT) that quantified the ability of serum antibodies to inhibit the binding of Spike RBD 4 to ACE2 receptor in vitro (Tan et al., 2020) . We also quantified anti-RBD, anti-S1 (S1 domain antibodies with a Luminex-based quantification test that utilize beads coated with RBD, S1 7 domain of Spike and NP proteins respectively ( Figure 2A ). 8 Figure 2B shows that all COVID-19 patients developed neutralising antibodies with the 9 exception of patient P02 who nonetheless cleared SARS-CoV-2 at day 13 post symptom 10 onset ( Figure 1 ). The peak neutralizing activity was achieved within 9-15 days post symptom 11 onset. Patients with moderate/severe symptoms exhibited a stronger virus-specific antibody 12 responses than those with mild disease (Supplementary Figure 1B and 1C ). Of note, the two 13 patients who first reached 90% virus neutralisation developed severe disease (P05-deceased 14 and P03-severe). The kinetics of anti-RBD, anti-S1 and anti-NP IgG also peaked around the 15 10-20 days period, similar to previous observations (Isho et al., 2020; Ripperger et al., 2020) 16 with higher peak levels of antibodies against NP and Spike detected in patient P05 who 17 succumbed to the infection. Interestingly, when we analysed in parallel the kinetics of 18 appearance of antibody responses against different proteins, we observed that patients 19 with severe disease have an early NP-biased antibody response, while those with 1 Spike IgG response in severe COVID-19 patients. 2 3 Dynamics of SARS-CoV-2 specific cellular responses 4 We next analysed the kinetics of functional SARS-CoV-2 specific T cell appearance during the of ORF1ab and a pool of ~40 peptides containing all the confirmed T cell epitopes of Spike 8 were used to stimulate PBMC in an IFN-γ ELISPOT assay ( Figure 3A ). 9 During the initial phase of SARS-CoV-2 infection, the quantity of IFN-γ secreting cells after 10 stimulation by the different peptides pools increased progressively with the peak of 11 frequency detected within ~15 days after symptom onset in the majority of the tested 12 patients (8 out of 12, Figure 3B and 3C) in line with previous reports (Weiskopf et al., 2020) 13 (Rydyznski Moderbacher et al., 2020) . In two patients, peak responses were detected 14 beyond 20 days after symptom onset, while patient P05, who succumbed to disease before 15 viral clearance, had no detectable IFN-γ secreting cells when stimulated with the different 16 peptide pools until day 26 when stimulation with Spike peptides activated a weak response 17 ( Figure 3B ). Importantly, production of IFN-γ was detected at all time points in all patients 18 after stimulation with PMA+Ionomycin, showing that global cellular functionality was not 19 fully compromised (Figure 4A insert). The frequency of IFN-γ secreting cells reactive to all 20 the different peptide pools was also quantified at least 1 month after resolution of infection. 21 The magnitude of the IFN-γ response declined markedly in 7 out of the 8 patients tested First, we observed that in contrast to the antibody quantity, the overall magnitude of SARS- 3 CoV-2 peptide-reactive cells was not proportional to the severity of disease. Figure 2B Figure 4A ). In line with our previous report, NSP7 and NSP13 1 pools were rarely able to trigger IFN-y responses in COVID-19 patients(Le Bert et al., 2020). 2 In most of the acute patients, we observed the simultaneous presence of IFN-y producing 3 cells specific for all the different peptide pools both during the acute phase of infection and 4 at convalescence ( Figure 4A ). Of note, we observed that the ORF 7/8 peptide pool triggered responsive T cells were CD4 cells but CD8 T cells specific to NP peptide pools were also 20 detected ( Figure 4D ). We were also able to expand ORF7 or ORF8 specific T cells in 6 out of 7 21 patients in whom we detected, in the early phases of infection, a robust population of IFN-y 22 producing cells after activation with the combined ORF7/8 peptide pools. Phenotypic 23 analysis showed that these cells were all CD4 T cells. Thus even though we were unable to 24 J o u r n a l P r e -p r o o f 9 directly demonstrate that CD4 T cells were responsible for the IFN-y response triggered by 1 ORF7/8 pools during the early phases of infection, such interpretation was strongly 2 supported by the exclusive expansion of ORF7 and ORF8 specific CD4 T cells in the 3 convalescents. SARS-CoV-2 specific T cells with disease severity (Peng et al., 2020) . However in this work, 10 the T cell response was measured in patients who were already in the convalescent phase. 11 Since our longitudinal analysis showed that the frequency of SARS-CoV-2 specific T cells 12 rapidly waned after SARS-CoV-2 clearance, the time of T cell analysis can significantly 13 influence the magnitude of T cell response detected. The most robust functional T cell 14 response was detected in patients with mild symptoms who cleared the virus early, while 15 for example in the patient with severe disease who succumbed to infection we could only 16 detect a weak and monospecific IFN-γ secreting cell response at 26 days after symptom 17 onset. These observations are in line with other studies where paucity of IFN-γ producing 18 SARS-CoV-2 specific T cells was observed in few patients with severe disease analyzed 19 during the early phase of disease (Weiskopf et al., 2020) (Rydyznski Moderbacher et al., 20 2020) (Zhou et al., 2020b) . This absence of IFN-γ producing SARS-CoV-2 specific T cells in the 21 peripheral blood of patients with severe disease could be caused by a defective induction of 22 SARS-CoV-2 T cells. Alternatively, a more robust sequestration of the cells in the highly 23 inflamed lung environment (Zhao et al., 2016) or a functional impairment of SARS-CoV-2 T 24 J o u r n a l P r e -p r o o f cells could also occur (Zhou et al., 2020b) . The latter possibility is also supported by recent 1 data obtained with different methods (HLA-multimers or single cell multi-omic analysis) 2 showing an impairment of IFN-γ production by SARS-CoV-2 specific T cells in COVID-19 3 recovered patients (Rha et al., 2020) and the presence of a population of proliferating 4 exhausted T cells during the early phases of severe COVID-19 (Su et al., 2020a) . 5 Additional studies would have to be performed in order to confirm and/or differentiate 6 these potential causes of the defect of SARS-CoV-2 T cells detected in more severe cases of 7 COVID-19. Ultimately, combining these data with our observations further stresses the 8 importance of an early and functional SARS-CoV-2 specific T cell response in reducing 9 infection and disease severity. 10 The opposite scenario was observed for antibodies. The two most severe COVID-19 patients 11 studied here showed the most rapid and robust ability to achieve peak virus neutralisation 12 and the overall quantities of SARS-CoV-2 specific antibodies were higher in severe than 13 milder COVID-19 cases. These data confirm the numerous observations that have linked 14 virus-specific antibody production (Hung et al., 2020; Long et al., 2020b 21 While the mechanism leading to the acquisition of the genomic change is unresolved, the 22 early induction of ORF7/8 specific T cells and a recent report of the robust early antibody 23 J o u r n a l P r e -p r o o f response to ORF8 in SARS-CoV-2 infection would suggest that an immune-driven selection 1 process could be involved (Hachim et al., 2020) . Given that this viral variant was associated 2 with a milder disease (Young et al., 2020) , the early induction of ORF7/8 immunity is worthy patients (Grifoni et al., 2020; Schulien et al., 2020) . It will be important to understand 14 whether the initial IFN-γ producing cells detected in the early phase of infections are 15 preferentially constituted by CD4 or CD8 T cells. 16 Despite these limitations, the direct association between early induction of IFN-γ producing Declaration of interest 20 1 receptors for treatment of virus-related diseases and cancers. None of the other authors has 2 any competing interest related to the study. 11 and the Luminex-based assay to quantify SARS-CoV-2 RBD-, S1-and NP-specific IgG and IgM 12 antibodies. A cut-off to define significant virus neutralisation or antibody quantities was set 13 at 20% inhibition for the sVNT assay (as defined in ref) and an MFI >100 for the Luminex 14 based assay respectively. B) SARS-CoV-2 neutralisation and the relative quantities of specific 15 IgG and antibodies (n=12). C) Rose plots represent the quantity of RBD-, S1-and NP-specific 16 IgG and IgM antibodies at the time of first detectable antibody response (n=12). Patient P02 17 has no detectable antibody response at 3, 4, 7 and 9 days after symptom onset where 18 samples were available. 19 20 number of days to the first detectable T cell response (Total, NP-specific, ORF7/8-specific, 10 ORF3a-specific, M-specific or Spike-specific T cell response) or antibody-related response 11 (sVNT, RBD-, S1-or NP-specific IgG and IgM) are shown in the respective dot plots. P-values 12 and the corresponding r 2 values are shown. The published article includes all datasets generated or analyzed during this study. This 9 study did not generate/analyze computer codes or algorithms. Surrogate virus neutralization assay 9 sVNT assay to quantify the neutralising antibody response were performed as previously 10 described (Tan et al., 2020) . Briefly, sera from acutely infected patients were prepared in 11 BSL3 containment and heat-inactivated prior to sVNT assay. HRP-conjugated RBD 12 (Genscript) were pre-incubated with 1:20 diluted serum at 37°C for 1h, followed by addition 13 to the Fc-chimeric human ACE2-coated MaxiSORP ELISA plate (Nunc) for an hour at room 14 temperature. Colorimetric signal was developed using TMB substrate (KPL) after extensive 15 PBST washes and the reaction was stopped with 1M HCl. Absorbance reading at 450 nm and 16 570 nm were obtained using Hidex Sense microplate reader (Hidex). 17 18 Luminex analysis 1 followed by 1:1000 diluted PE-conjugated anti-human IgG polyclonal antibody (eBioscience) 2 or PE-conjugated anti-human IgM antibody (SouthernBiotech) for 1h at room temperature. 3 The signal was detected using Luminex MAGPIX instrument. Table 2 ). CPT tubes 10 were centrifuged at 1500 rcf for 15 mins and approximately 2 ml of mononuclear cells 11 located on top of the polyester gel were aliquoted and stored at -80°C. ELISPOT plates were 12 prepared with anti-human IFN-γ coating antibody (MabTech) and peptides pools in 50 µl 13 AIM-V medium (Gibco; Thermo Fisher Scientific) supplemented with 2% AB human serum 14 (Gibco; Thermo Fisher Scientific) on the day of incubation with PBMCs. Vials containing 15 PBMCs were thawed at RT, 2U Benzonase (SigmaAldrich) to remove remaining nucleic acids 16 was added when fully thawed and incubated for 15 mins before centrifugation at 1000 rcf 17 for 10 mins. The cell pellet was dissolved in 1 ml of AIM-V medium (Gibco; Thermo Fisher 18 Scientific) supplemented with 2% AB human serum (Gibco; Thermo Fisher Scientific) before 19 quantification at undiluted and 1:10 dilution using a Scepter 2.0 cell counter (Millipore). 20 Approximately 2 x 10 5 PBMCs in 100 µl per well were incubated in the presence of peptides 21 overnight at 37°C and 5% CO2. After 24 hours, inoculum was removed and plates were 22 washed six times with PBS. Biotinylated anti-human IFN-γ antibody (MabTech) at a 1:2000 23 J o u r n a l P r e -p r o o f dilution in PBS/0.5% FCS was incubated at RT for two hours, followed by six wash steps with 1 PBS and incubation of Streptavidin-ALP (MabTech) at a 1:2000 dilution in PBS/0.5% FCS at 2 RT for one hour. After another six PBS washes, 50µl of KPL BCIP/NBT phosphatase substrate 3 (SeraCare) was added and incubated at RT in the dark for 5-15 mins. The reaction was 4 stopped by washing the plate with water extensively when the chromogenic reaction 5 produced clearly visible spots. Subsequently, the plates were allowed to air-dry and spot 6 forming units (SFU) were analysed using an Immunospot reader and software (Cellular 7 Technology Limited). 10 T cell lines were generated as follows: 20% of PBMC were pulsed with 10 μg/ml of the 11 overlapping SARS-CoV-2 peptides (all pools combined) or single peptides for 1 hour at 37°C, 12 subsequently washed, and co-cultured with the remaining cells in AIM-V medium (Gibco; 13 Thermo Fisher Scientific) supplemented with 2% AB human serum (Gibco; Thermo Fisher 14 Scientific). T cell lines were cultured for 10 days in the presence of 20 U/ml of recombinant 15 IL-2 (R&D Systems). 16 17 Flow cytometry analysis 1 Cytofix/Cytoperm kit (BD Biosciences-Pharmingen) and stained with anti-human IFN-γ PE 2 (clone 25723, R&D Systems; 1:25) and analysed on a BD-LSR II FACS Scan. Data were 3 analysed by Kaluza (Beckman Coulter). Antibodies were purchased from BD Biosciences- 4 Pharmingen unless otherwise stated. All statistical analysis were performed using GraphPad Prism v7. Where applicable, the 8 statistical tests used and the definition of centre were indicated in the figure legends. 9 Statistical significance was defined as having a P-value of less than 0.05. In all instances, "n" 10 refers to the number of patients analysed. 

Distinct Early Serological Signatures Track with SARS-CoV

SARS-CoV-2-reactive T cells in healthy 6 donors and patients with COVID-19

Clinical and immunological features of severe and moderate coronavirus 9 disease 2019

Targets of T Cell Responses to

SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Humoral 16 Immune Response to SARS-CoV-2 in Iceland

ORF8 and ORF3b antibodies are 19 accurate serological markers of early and late SARS-CoV-2 infection

Selective and cross-reactive SARS-CoV-2 T cell 2 epitopes in unexposed humans

Broad and strong memory CD4+ and CD8+ T cells induced by

SARS-CoV-2 in UK convalescent individuals following COVID-19

IFN-γ is Produced by Pd-1 + Cells Among SARS-CoV-2-Specific MHC-I 9

Multimer+CD8 + T Cells in Acute and Convalescent COVID-19 Patients. Available at SSRN: 10

CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal 14

Antigen-Specific Adaptive Immunity 17 to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Characterization of pre-existing and induced SARS-21

mediated blockage of ACE2-spike protein-protein interaction

Kinetics of viral load and antibody response in relation to COVID-19 4 severity

Phenotype 7 and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory 8 distress syndrome

Extrafollicular B cell responses correlate 11 with neutralizing antibodies and morbidity in COVID-19

Effects of a major deletion in the SARS-CoV-2 14 genome on the severity of infection and the inflammatory response: an observational 15 cohort study

Airway Memory CD4 + T 18

Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses

A pneumonia outbreak associated with a new coronavirus of probable 22 bat origin

Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell 25 Responses